enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been given a consensus recommendation of “Buy” by the ten research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $25.22.

ENGN has been the topic of several analyst reports. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Citizens Jmp raised enGene to a “strong-buy” rating in a research report on Monday, November 18th. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of enGene in a research note on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Finally, Piper Sandler began coverage on shares of enGene in a research report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 price objective on the stock.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Fcpm Iii Services B.V. raised its stake in shares of enGene by 11.0% in the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company’s stock worth $64,057,000 after buying an additional 954,610 shares during the period. VR Adviser LLC raised its stake in enGene by 41.5% during the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company’s stock worth $33,559,000 after acquiring an additional 1,480,573 shares during the period. Deep Track Capital LP boosted its position in shares of enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company’s stock worth $30,308,000 after purchasing an additional 1,949,942 shares during the period. Blue Owl Capital Holdings LP increased its stake in shares of enGene by 3.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after purchasing an additional 101,006 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of enGene by 84.7% during the 4th quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company’s stock valued at $8,145,000 after purchasing an additional 561,797 shares during the period. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

enGene Trading Up 0.9 %

NASDAQ ENGN opened at $5.40 on Friday. The stock’s fifty day moving average price is $6.51 and its 200-day moving average price is $7.12. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market cap of $275.28 million, a P/E ratio of -9.31 and a beta of -0.61. enGene has a 12 month low of $4.42 and a 12 month high of $18.40.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. As a group, equities analysts forecast that enGene will post -1.56 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.